Download PDF
1 / Pages

Other users also viewed these articles

Analysis of the evolocumab (Repatha®) patient support program for patients with cardiovascular disease in Colombia Ángel Alberto García-Peña; Mariana Pineda-Posada; Carol Páez-Canro; César Cruz; Daniel Samacá-Samacá;
Clin Investig Arterioscler. 2023;35:280-9
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study Agustín Blanco Echevarría; Juan De Dios García Díaz; Assumpta Caixas; Núria Plana Gil; Miguel Ángel Rico Corral; Ian Bridges; Nafeesa Dhalwani; Sònia Gatell Menchen; Kausik K. Ray;
Clin Investig Arterioscler. 2023;35:263-71
Analysis of the prescription process of PCSK9 inhibitors in the cardiology departments of Spanish hospitals and optimization proposal. The IKIGAI study Vivencio Barrios; Carlos Escobar; Vicente Arrarte; Marisol Bravo; Alfredo del Campo; Rafael Hidalgo; Lluís Recasens; Ángel Cequier;
Clin Investig Arterioscler. 2021;33:296-305